MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/ijo.ijo_2693_25

Медицинская библиотека · Indian journal of ophthalmology · 2026

A randomized controlled study to compare the efficacy of intravitreal faricimab 6.0 mg versus aflibercept 2.0 mg in management of treatment-naive diabetic macular edema in Indian populations.

Mishra Sanjay, Dutt Mrida, Kumar Pradeep, Joshi Amrita, Sati Alok, Dhar Supriya, Avasthi Abhijeet, Khaleel M, Srujana D, Gupta Ashutosh

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Diabetic macular edema (DME) is a leading cause of vision loss among patients with diabetes. Anti-VEGF agents such as aflibercept have long been the cornerstone of treatment, though frequent dosing imposes a significant burden. faricimab, a bispecific antibody targeting both VEGF-A and angiopoietin-2, has emerged as a novel alternative with the potential for extended durability. Evidence from Indian populations remains limited, warranting comparative evaluation.

METHODS

This randomized controlled trial was conducted at a tertiary care institute from January 2024 to June 2025. Seventy-four treatment-naïve DME patients were randomized equally to receive either intravitreal faricimab (6.0 mg) or aflibercept (2.0 mg). All patients received three loading doses at 4-week intervals followed by as-needed retreatment based on functional and anatomical criteria. Primary outcomes included changes in best-corrected visual acuity and central macular thickness at 48 weeks. Secondary outcomes were injection frequency and safety profile.

RESULTS

Both groups were comparable at baseline. At 48 weeks, mean BCVA improvement was similar (AFL: -0.366 logMAR; FAR: -0.374 logMAR, p=NS). CMT reduction was equivalent between groups (AFL: -119 µm; FAR: -132 µm, p=NS). Faricimab achieved significantly longer mean dosing intervals (12.86 vs. 9.47 weeks, p<0.001) with fewer injections required at maintenance phase. Safety profiles were similar, with only mild, transient adverse events reported.

CONCLUSION

Faricimab demonstrated equivalent efficacy and safety to aflibercept in treatment-naïve Indian DME patients, with the added advantage of reduced injection burden and longer treatment intervals.

Для цитирования: Mishra Sanjay, Dutt Mrida, Kumar Pradeep, Joshi Amrita, Sati Alok, Dhar Supriya, Avasthi Abhijeet, Khaleel M, Srujana D, Gupta Ashutosh. A randomized controlled study to compare the efficacy of intravitreal faricimab 6.0 mg versus aflibercept 2.0 mg in management of treatment-naive diabetic macular edema in Indian populations.. Indian journal of ophthalmology. 2026. DOI: 10.4103/ijo.ijo_2693_25.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.